Revelation Biosciences (REVB) Competitors

Revelation Biosciences (NASDAQ:REVB) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Is REVB or NBY more profitable?

Revelation Biosciences has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Revelation Biosciences' return on equity of -193.51% beat NovaBay Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-193.51%	-84.00%
NovaBay Pharmaceuticals	-102.72%	-7,293.78%	-158.41%

Does the media prefer REVB or NBY?

In the previous week, Revelation Biosciences had 6 more articles in the media than NovaBay Pharmaceuticals. MarketBeat recorded 6 mentions for Revelation Biosciences and 0 mentions for NovaBay Pharmaceuticals. NovaBay Pharmaceuticals' average media sentiment score of 0.00 beat Revelation Biosciences' score of -0.55 indicating that NovaBay Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Revelation Biosciences	Negative
NovaBay Pharmaceuticals	Neutral

Which has more volatility & risk, REVB or NBY?

Revelation Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Do analysts rate REVB or NBY?

NovaBay Pharmaceuticals has a consensus price target of $0.85, suggesting a potential upside of 41.67%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NovaBay Pharmaceuticals is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NovaBay Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings & valuation, REVB or NBY?

Revelation Biosciences has higher earnings, but lower revenue than NovaBay Pharmaceuticals. NovaBay Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120K	-$102.61	-0.01
NovaBay Pharmaceuticals	$9.78M	0.36	-$9.64M	-$53.72	-0.01

Do institutionals and insiders hold more shares of REVB or NBY?

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 0.1% of Revelation Biosciences shares are held by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor REVB or NBY?

Revelation Biosciences received 29 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 62.50% of users gave Revelation Biosciences an outperform vote while only 1.47% of users gave NovaBay Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Revelation Biosciences	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%
NovaBay Pharmaceuticals	Outperform Votes 1 1.47%	Underperform Votes 67 98.53%

Summary

NovaBay Pharmaceuticals beats Revelation Biosciences on 9 of the 17 factors compared between the two stocks.